Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their use.

“My son’s lips, at this point, started to turn blue. He also had a febrile seizure, which is why his body was stiff and ...

A nasal vaccine for COVID-19—based on technology developed at Washington University in St. Louis—is poised to enter a phase 1 ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

COVID-19 was associated with more severe disease outcomes than influenza or respiratory syncytial virus (RSV) during the 2022 to 2023 season.

The virus is a common respiratory illness that infects the lungs and airways. Most people experience mild symptoms, like the common cold. However, RSV can cause more severe symptoms in infants, older ...

LONDON - Shionogi & Co., Ltd. (TYO:4507) has reported positive outcomes from its Phase 2a human challenge trial for an investigational oral antiviral candidate targeting Respiratory Syncytial Virus ...

Flu cases have been particularly prevalent in the Wood River Valley this winter, according to St. Luke’s Wood River data.

There is already a clutch of candidate RSV vaccines in late-stage development – including GSK's own shot which is heading for regulatory filings after clearing a phase 3 test last month – but ...

Other potential microplastics sources our experts brought up are fabrics that touch your skin often (clothing, bedding, ...

Merck, the giant pharmaceutical company with multiple facilities in eastern Pennsylvania and New Jersey, isn’t too enthused ...

ST. CLAIR COUNTY, Ill. – One person was left injured Wednesday morning after a vehicle was partially trapped underneath a ...